Real World, Translational Dimensions of New LDL-Targeted Therapies: What Have the Trials Taught Us About the Efficacy, Clinical Indications, Regimen Adherence, Dosing Considerations and Safety Profiles of PCSK9 Inhibitors and Other Novel Targets for CV Risk Reduction Across the CV Morbidity Continuum